Novartis (NVS)
(Real Time Quote from BATS)
$107.10 USD
-4.70 (-4.20%)
Updated Jul 18, 2024 03:55 PM ET
After-Market: $107.23 +0.13 (0.12%) 4:12 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Net sales to third parties
- 44,635.00
- 50,545.00
- 51,626.00
- 48,659.00
- 47,445.00
- Revenue - Line of Business (LOBR)
- Revenues: Other revenues
- 1,220.00
- 1,283.00
- 1,251.00
- 1,239.00
- 1,179.00
- Revenue - Line of Business (LOBR)
- Revenues: Cardiovascular: Entresto: Total
- 6,035.00
- 4,644.00
- 3,548.00
- 2,497.00
- 1,726.00
- Revenue - Line of Business (LOBR)
- Revenues: Immunology: Cosentyx: Total
- 4,980.00
- 4,788.00
- 4,718.00
- 3,995.00
- 3,551.00
- Revenue - Line of Business (LOBR)
- Revenues: Immunology: Xolair: Total
- 1,463.00
- 1,365.00
- 1,428.00
- 1,251.00
- 1,173.00
- Revenue - Line of Business (LOBR)
- Revenues: Immunology: Ilaris: Total
- 1,355.00
- 1,133.00
- 1,059.00
- 873.00
- 671.00
- Revenue - Line of Business (LOBR)
- Revenues: Neuroscience: Gilenya: Total
- 925.00
- 2,013.00
- 2,787.00
- 3,003.00
- 3,223.00
- Revenue - Line of Business (LOBR)
- Revenues: Solid Tumors: Tafinlar + Mekinist: Total
- 1,922.00
- 1,770.00
- 1,693.00
- 1,542.00
- 1,338.00
- Revenue - Line of Business (LOBR)
- Revenues: Solid Tumors: Kisqali: Total
- 2,080.00
- 1,231.00
- 937.00
- 687.00
- 480.00
- Revenue - Line of Business (LOBR)
- Neuroscience: Kesimpta
- 2,171.00
- 1,092.00
- 372.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Established Brands: Galvus Group: Total
- 692.00
- 859.00
- 1,092.00
- 1,199.00
- 1,297.00
- Revenue - Line of Business (LOBR)
- Total Established Brand
- 13,618.00
- 15,949.00
- 12,241.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Other Promoted Brands: Lucentis: Total
- 1,475.00
- 1,874.00
- 2,160.00
- 1,933.00
- 2,086.00
- Revenue - Line of Business (LOBR)
- Established Brands: Other
- 5,427.00
- 6,113.00
- 4,257.00
- --
- --
- Revenue - Line of Business (LOBR)
- Solid Tumors: Lutathera
- 605.00
- 471.00
- 475.00
- --
- --
- Revenue - Line of Business (LOBR)
- Established Brands: Contract manufacturing
- 1,490.00
- 1,200.00
- 108.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Established Brands: Exforge Group: Total
- 713.00
- 743.00
- 901.00
- 980.00
- 1,025.00
- Revenue - Line of Business (LOBR)
- Total Promoted Brands
- 31,822.00
- 26,257.00
- 29,754.00
- --
- --
- Revenue - Line of Business (LOBR)
- Total Neuroscience
- 4,043.00
- 3,038.00
- 5,007.00
- --
- --
- Revenue - Line of Business (LOBR)
- Total Cardiovascular
- 6,391.00
- 4,756.00
- 3,560.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Hematology: Tasigna: Total
- 1,848.00
- 1,923.00
- 2,060.00
- 1,542.00
- 1,880.00
- Revenue - Line of Business (LOBR)
- Total Immunology
- 7,798.00
- 7,287.00
- 7,205.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Established Brands: Diovan Group: Total
- 613.00
- 652.00
- 773.00
- 1,003.00
- 1,064.00
- Revenue - Line of Business (LOBR)
- Cardiovascular: Leqvio
- 355.00
- 112.00
- 12.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Hematology: Promacta/Revolade: Total
- 2,269.00
- 2,088.00
- 2,016.00
- 1,738.00
- 1,416.00
- Revenue - Line of Business (LOBR)
- Neuroscience: Aimovig
- 266.00
- 218.00
- 215.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Hematology: Jakavi: Total
- 1,720.00
- 1,561.00
- 1,595.00
- 1,339.00
- 1,114.00
- Revenue - Line of Business (LOBR)
- Hematology: Scemblix
- 413.00
- 149.00
- 7.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Hematology: Kymriah: Total
- 508.00
- 536.00
- 587.00
- 474.00
- 278.00
- Revenue - Line of Business (LOBR)
- Neuroscience: Zolgensma
- 1,214.00
- 1,370.00
- 1,351.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Established Brands: Sandostatin: Total
- 1,314.00
- 1,238.00
- 1,413.00
- 1,439.00
- 1,585.00
- Revenue - Line of Business (LOBR)
- Solid Tumors: Pluvicto
- 980.00
- 271.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Solid Tumors: Piqray
- 505.00
- 373.00
- 329.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Cardiovascular: Entresto: US
- 3,067.00
- 2,354.00
- 1,712.00
- 1,277.00
- 925.00
- Revenue - Geographic (GEOR)
- Revenues: Cardiovascular: Entresto: ROW
- 2,968.00
- 2,290.00
- 1,836.00
- 1,220.00
- 801.00
- Revenue - Geographic (GEOR)
- Revenues: Neuroscience: Gilenya: US
- 359.00
- 1,153.00
- 1,427.00
- 1,562.00
- 1,736.00
- Revenue - Geographic (GEOR)
- Revenues: Neuroscience: Gilenya: ROW
- 566.00
- 860.00
- 1,360.00
- 1,441.00
- 1,487.00
- Revenue - Geographic (GEOR)
- Revenues: Hematology: Tasigna: US
- 884.00
- 877.00
- 882.00
- 569.00
- 804.00
- Revenue - Geographic (GEOR)
- Revenues: Hematology: Tasigna: ROW
- 964.00
- 1,046.00
- 1,178.00
- 973.00
- 1,076.00
- Revenue - Geographic (GEOR)
- Revenues: Solid Tumors: Tafinlar + Mekinist: US
- 791.00
- 678.00
- 606.00
- 569.00
- 481.00
- Revenue - Geographic (GEOR)
- Revenues: Solid Tumors: Tafinlar + Mekinist: ROW
- 1,131.00
- 1,092.00
- 1,087.00
- 973.00
- 857.00
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Exforge Group: US
- 13.00
- 14.00
- 14.00
- 16.00
- 13.00
- Revenue - Geographic (GEOR)
- Revenues: Hematology: Promacta/Revolade: ROW
- 1,064.00
- 1,005.00
- 1,069.00
- 905.00
- 725.00
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Diovan Group: ROW
- 561.00
- 597.00
- 722.00
- 879.00
- 978.00
- Revenue - Geographic (GEOR)
- Revenues: Solid Tumors: Kisqali: US
- 1,032.00
- 472.00
- 339.00
- 318.00
- 250.00
- Revenue - Geographic (GEOR)
- Revenues: Solid Tumors: Kisqali: ROW
- 1,048.00
- 759.00
- 598.00
- 369.00
- 230.00
- Revenue - Geographic (GEOR)
- Neuroscience: Zolgensma: US
- 372.00
- 434.00
- 469.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Immunology: Cosentyx: ROW
- 2,344.00
- 2,018.00
- 4,718.00
- 1,479.00
- 1,331.00
- Revenue - Geographic (GEOR)
- Revenues: Hematology: Promacta/Revolade: US
- 1,205.00
- 1,083.00
- 947.00
- 833.00
- 691.00
- Revenue - Geographic (GEOR)
- Revenues: Immunology: Cosentyx: US
- 2,636.00
- 2,770.00
- 2,883.00
- 2,516.00
- 2,220.00
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Sandostatin: US
- 829.00
- 800.00
- 843.00
- 837.00
- 881.00
- Revenue - Geographic (GEOR)
- Neuroscience: Zolgensma: ROW
- 842.00
- 936.00
- 882.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Exforge Group: ROW
- 700.00
- 729.00
- 887.00
- 964.00
- 1,012.00
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Sandostatin: ROW
- 485.00
- 438.00
- 570.00
- 602.00
- 704.00
- Revenue - Geographic (GEOR)
- Revenues: Immunology: Ilaris: US
- 686.00
- 570.00
- 501.00
- 400.00
- 304.00
- Revenue - Geographic (GEOR)
- Revenues: Immunology: Ilaris: ROW
- 669.00
- 563.00
- 558.00
- 473.00
- 367.00
- Revenue - Geographic (GEOR)
- Revenues: Established Brands: Diovan Group: US
- 52.00
- 55.00
- 51.00
- 124.00
- 86.00